Abstract
Protein tyrosine phosphatases (PTPs) are a large family of signaling enzymes playing critical role in signal transduction and regulation of cellular processes. Dysfunction of PTP activity is associated with diabetes, cancer, autoimmune disorders, and neural diseases. PTP inhibitors therefore emerged as promising therapeutic targets. Recent research indicates that besides small organic molecules, metal ions and metal complexes can also strongly inhibit PTPs both in vitro and in vivo, resulting in the increase of phosphorylation of corresponding substrates and the modulation of cellular process. Structure of metal complexes influences the potency and selectivity of PTP inhibition. Detailed studies on this subject are not only expected to yield metal-based drugs targeting individual PTPs, but also to support understanding the function of metals in organisms. This review focuses on recent advancements in this area of research.
Keywords: Protein tyrosine phosphatases, inhibitor, metal ions, vanadium complexes, copper complexes, zinc complexes, gold complexes, metal complexes, selectivity, phosphorylation, HPTP
Anti-Cancer Agents in Medicinal Chemistry
Title: Metal-Based Inhibitors of Protein Tyrosine Phosphatases
Volume: 11 Issue: 1
Author(s): Liping Lu and Miaoli Zhu
Affiliation:
Keywords: Protein tyrosine phosphatases, inhibitor, metal ions, vanadium complexes, copper complexes, zinc complexes, gold complexes, metal complexes, selectivity, phosphorylation, HPTP
Abstract: Protein tyrosine phosphatases (PTPs) are a large family of signaling enzymes playing critical role in signal transduction and regulation of cellular processes. Dysfunction of PTP activity is associated with diabetes, cancer, autoimmune disorders, and neural diseases. PTP inhibitors therefore emerged as promising therapeutic targets. Recent research indicates that besides small organic molecules, metal ions and metal complexes can also strongly inhibit PTPs both in vitro and in vivo, resulting in the increase of phosphorylation of corresponding substrates and the modulation of cellular process. Structure of metal complexes influences the potency and selectivity of PTP inhibition. Detailed studies on this subject are not only expected to yield metal-based drugs targeting individual PTPs, but also to support understanding the function of metals in organisms. This review focuses on recent advancements in this area of research.
Export Options
About this article
Cite this article as:
Lu Liping and Zhu Miaoli, Metal-Based Inhibitors of Protein Tyrosine Phosphatases, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941271
DOI https://dx.doi.org/10.2174/187152011794941271 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Bone Density Measurements in the Evaluation of New Treatments for Osteoporosis
Current Pharmaceutical Design Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Quinone Bioreductive Prodrugs as Delivery Agents
Current Drug Delivery Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology An Integrative “Omics” Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal Adenocarcinoma
Current Cancer Drug Targets Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Acknowledgements to Reviewers
Current Cancer Therapy Reviews Polycation-Based Gene Therapy: Current Knowledge and New Perspectives
Current Gene Therapy Recent Advancements in Organotin(IV) Complexes as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Meet Our Editorial Board Member
Current Gene Therapy Editorial [Hot Topic: Perspectives in Integrin Blocking (Executive Editor: C. Marcinkiewicz)]
Current Pharmaceutical Design Liposomes in Active, Passive and Acoustically-Triggered Drug Delivery
Mini-Reviews in Medicinal Chemistry lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience